Literature DB >> 12660947

Role of neuraminidase in lethal synergism between influenza virus and Streptococcus pneumoniae.

Jonathan A McCullers1, Kimberly C Bartmess.   

Abstract

A lethal synergism exists between influenza virus and Streptococcus pneumoniae, accounting for excess mortality during influenza epidemics. Using a model of viral-bacterial synergism, we assessed the role that the influenza virus neuraminidase (NA) has in priming mice for pneumococcal infection. Administration of the selective NA inhibitor oseltamivir improved survival, independent of viral replication and morbidity from influenza. Both pathologic examination of the lungs and live imaging of pneumonic lesions, using a bioluminescent pneumococcus, suggested that the effect of NA inhibition was to limit the extent of pneumococcal pneumonia during early infection. Adherence assays and immunohistochemical staining for sialic acids in lungs from infected mice demonstrated that the influenza virus NA potentiates development of pneumonia by stripping sialic acid from the lung, thus exposing receptors for pneumococcal adherence. Selective NA inhibitors may be useful clinically to interrupt this novel mechanism of synergism and to prevent excess mortality from secondary bacterial pneumonia.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12660947     DOI: 10.1086/368163

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  168 in total

1.  The use of antimicrobial agents after diagnosis of viral respiratory tract infections in hospitalized adults: antibiotics or anxiolytics?

Authors:  Kevin T Shiley; Ebbing Lautenbach; Ingi Lee
Journal:  Infect Control Hosp Epidemiol       Date:  2010-11       Impact factor: 3.254

2.  Influenza virus primes mice for pneumonia from Staphylococcus aureus.

Authors:  Amy R Iverson; Kelli L Boyd; Julie L McAuley; Lisa R Plano; Mark E Hart; Jonathan A McCullers
Journal:  J Infect Dis       Date:  2011-01-28       Impact factor: 5.226

Review 3.  Do multiple concurrent infections in African children cause irreversible immunological damage?

Authors:  Sarah J Glennie; Moffat Nyirenda; Neil A Williams; Robert S Heyderman
Journal:  Immunology       Date:  2012-02       Impact factor: 7.397

Review 4.  Microbe hunting.

Authors:  W Ian Lipkin
Journal:  Microbiol Mol Biol Rev       Date:  2010-09       Impact factor: 11.056

5.  LPS-induced cytokine production in human dendritic cells is regulated by sialidase activity.

Authors:  Nicholas M Stamatos; Ivan Carubelli; Diantha van de Vlekkert; Erik J Bonten; Nadia Papini; Chiguang Feng; Bruno Venerando; Alessandra d'Azzo; Alan S Cross; Lai-Xi Wang; Peter J Gomatos
Journal:  J Leukoc Biol       Date:  2010-09-08       Impact factor: 4.962

Review 6.  Noninvasive biophotonic imaging for studies of infectious disease.

Authors:  Nuria Andreu; Andrea Zelmer; Siouxsie Wiles
Journal:  FEMS Microbiol Rev       Date:  2010-10-19       Impact factor: 16.408

7.  Influenza A inhibits Th17-mediated host defense against bacterial pneumonia in mice.

Authors:  Anupa Kudva; Erich V Scheller; Keven M Robinson; Chris R Crowe; Sun Mi Choi; Samantha R Slight; Shabaana A Khader; Patricia J Dubin; Richard I Enelow; Jay K Kolls; John F Alcorn
Journal:  J Immunol       Date:  2010-12-22       Impact factor: 5.422

8.  Deletions in the neuraminidase stalk region of H2N2 and H9N2 avian influenza virus subtypes do not affect postinfluenza secondary bacterial pneumonia.

Authors:  Ashok K Chockalingam; Danielle Hickman; Lindomar Pena; Jianqiang Ye; Andrea Ferrero; Jose R Echenique; Hongjun Chen; Troy Sutton; Daniel R Perez
Journal:  J Virol       Date:  2012-01-25       Impact factor: 5.103

9.  Sialidase-based anti-influenza virus therapy protects against secondary pneumococcal infection.

Authors:  Maria Hedlund; Laura M Aschenbrenner; Kellie Jensen; Jeffrey L Larson; Fang Fang
Journal:  J Infect Dis       Date:  2010-04-01       Impact factor: 5.226

10.  Regulation of IFN-γ by IL-13 dictates susceptibility to secondary postinfluenza MRSA pneumonia.

Authors:  Agnieszka Rynda-Apple; Ann Harmsen; Anfin S Erickson; Kyle Larson; Rachelle V Morton; Laura E Richert; Allen G Harmsen
Journal:  Eur J Immunol       Date:  2014-09-01       Impact factor: 5.532

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.